Skip to main content
. 2019 Feb 19;10:85. doi: 10.3389/fendo.2019.00085

Table 1.

Main clinical features and indications for treatment in osteopetrosis.

Gene Autosomal recessive osteopetrosis Overall disease severity Hematological defects Visual defects Hypocalcemia Growth retardation Primary neurodegeneration Indication to HSCT
TCIRG1 Osteoclast-rich form Most often severe Severe Mild to severe Severe Mild to severe No Yes
ClCN7 Osteoclast-rich form Severe to mild Mild to severe Mild to severe Severe Mild to severe Yes To be evaluated based on the severity of CNS involvement
OSTM1 Osteoclast-rich form Severe Mild to severe Mild to severe Moderate Mild to severe Yes No severe CNS involvement
SNX10 Osteoclast-rich form Variable Severe Severe Mild Mild No Yes
CAII Osteoclast-rich form Moderate None Mild Mild Moderate Cerebral calcification To be evaluated based on cerebral calcification
PLEKHM1 Osteoclast-rich form Mild None None None None to moderate No No mild presentation
FERMT3 Osteoclast-rich form Severe Severe Mild Mild Mild No Yes
NEMO Osteoclast-rich form Severe Severe None Mild Moderate No Yes
TNFRSF11A/RANK Osteoclast-poor form Most often severe Mild Mild Mild Moderate No Yes
TNFSF11/RANKL Osteoclast-poor form Intermediate Mild Mild Mild Severe No No